Evotec AG (EVTCY) Receives “Buy” Rating from Berenberg Bank

Berenberg Bank restated their buy rating on shares of Evotec AG (NASDAQ:EVTCY) in a report issued on Saturday morning.

A number of other brokerages have also commented on EVTCY. Deutsche Bank AG reiterated a neutral rating on shares of Evotec AG in a research note on Wednesday, May 3rd. Zacks Investment Research upgraded shares of Evotec AG from a hold rating to a buy rating and set a $17.00 price target on the stock in a research note on Tuesday, February 14th. Finally, DZ Bank AG reiterated a neutral rating on shares of Evotec AG in a research note on Friday, February 10th.

Shares of Evotec AG (NASDAQ:EVTCY) traded down 1.64% during mid-day trading on Friday, hitting $27.54. The stock had a trading volume of 1,057 shares. The stock has a market cap of $1.92 billion and a price-to-earnings ratio of 49.89. Evotec AG has a one year low of $7.80 and a one year high of $29.45. The firm has a 50 day moving average of $23.58 and a 200 day moving average of $17.15.

Evotec AG (NASDAQ:EVTCY) last announced its quarterly earnings results on Tuesday, March 28th. The company reported $0.32 EPS for the quarter. The company had revenue of $47.36 million during the quarter.

TRADEMARK VIOLATION WARNING: This piece of content was reported by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this piece of content on another domain, it was illegally stolen and republished in violation of U.S. & international copyright and trademark laws. The legal version of this piece of content can be accessed at https://sportsperspectives.com/2017/05/20/evotec-ag-evtcy-receives-buy-rating-from-berenberg-bank.html.

About Evotec AG

Evotec AG is a drug discovery and development company. The Company operates through two segments. The EVT Execute segment provides standalone drug discover services on a typical fee-for-service basis or integrated drug discovery collaborations on partners’ target through a range of commercial structures, including research fees, milestones and/or royalties.

12 Month Chart for NASDAQ:EVTCY

Receive News & Ratings for Evotec AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evotec AG and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply